Essential thrombocythemia terminating in pure erythroleukemia

American Journal of Hematology

Volumn 77, Issue 2, 2004, Pages 140-143

  Kreft, Andreas ^a   Burg, Jürgen ^a   Fischer, Thomas ^a   Kirkpatrick, Charles James ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Erythroleukemia; Essential thrombocythemia; Secondary acute leukemia

Indexed keywords

CYTARABINE; DAUNORUBICIN; HYDROXYUREA;

ADULT; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CASE REPORT; CELL DIFFERENTIATION; CELL LINEAGE; CLINICAL FEATURE; DISEASE COURSE; DOSE RESPONSE; ERYTHROID CELL; ERYTHROLEUKEMIA; HEMATOPOIETIC STEM CELL; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MALE; MEGAKARYOBLAST; MEGAKARYOCYTE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; THROMBOCYTHEMIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CELL TRANSFORMATION, NEOPLASTIC; FATAL OUTCOME; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MALE; MIDDLE AGED; THROMBOCYTOSIS; TIME FACTORS;

EID: 4644351278     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20164     Document Type: Article

References (31)

1. Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of tumors: pathology and genetics of tumours of the haematopoetic and lymphoid tissues. Lyon: IARC Press: 2001. p 39-41.
2. Anastasi J, Feng J, Le Beau MM, Larson RA, Rowley JD, Vardiman JW. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia 1995;9:628-633.
3. Ahuja H, Bar-Eli M, Arlin Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991;87:2042-2047.
4. Groupe Français de Cytogénétique Hématologique. Cytogenetics of acutely transformed chronic myeloproliferative syndromes without a Philadelphia chromosome. A multicenter sludy with 55 patients. Cancer Genet Cytogenet 1988;32:157-168.
5. Vardiman JW, Pierre R, Thiele J, Imbert M, Brunning RD, Flandrin G. Chronic myelogenous leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of tumors: pathology and genetics of tumours of the haematopoetic and lymphoid tissues. Lyon: IARC Press: 2001. p 20-26.
6. Thiele J, Pierre R, Imbert M, Vardimann JW, Brunning RD, Flandrin G. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of tumors: pathology and genetics of tumours of the haematopoetic and lymphoid tissues. Lyon: IARC Press; 2001. p 35-38.
7. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622.
8. Bernasconi P, Boni M, Cavigliano S, et al. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia 2002;16:2078-2083.
9. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology 2003;200-224.
10. Liozon E, Brigaudeau C, Trimoreau F, et al. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukemic transformation and review of the literature. Hematol Cell Ther 1997;39:11-18.
11. Radaelli F, Mazza R. Curioni E, Chiani A, Pomati M, Naiolo A-T. Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution? Eur J Haematol 2002;69:108-111.
12. Frei-Lahr D, Barton JC, Hoffman R. Elastic transformation of essential thrombocythemia: dual expression of myelomonoblastic/megakaryoblastic phenotypes. Blood 1984;63:866-872.
13. El-Kassar N, Hetet G, Brière J, Grandchamp B. Clonality analysis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 1997;89:128-134.
14. Van L, El-Kassar N, Gardin C, Brière J. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia. Leuk Lymphoma 1996;22(Suppl 1):31-40.
15. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417-424.
16. Georgii A, Büsche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 1998;11:721-749.
17. Park S, Picard F, Azgui Z, et al. Erythroleukemia: a comparison between the previous FAB approach and the WHO classification. Leuk Res 2002;26:423-429.
18. Domingo-Claros A, Larriba I, Rozman M, et al. Acute erythroid neoplastic proliferations: a biological study based on 62 patients. Haematologica 2002;87:148-153.
19. Goldberg SL, Noel P, Klumpp TR, Dewald GW. The erythroid leukemias: a comparative study of Erythroleukemia (FAB M6) and Di Gugliemo disease. Am J Clin Pathol 1998;21:42-47.
20. Brunning RD, Matutes E, Flandrin G, Vardiman JW, Bennet J, Harris NL. Acute myeloid leukaemia not otherwise categorised. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of tumors: pathology and genetics of tumours of the haematopoetic and lymphoid tissues. Lyon: IARC Press; 2001. p 55-65.
21. Shividasani RA. Molecular and transcriptional regulation of megakaryocyte differentiation. Stem Cells 2001;19:397-407.
22. Gregg XT, Liu Y. Prchal JF, Gartland GL, Cooper MD, Prchal JT. Clonality in myeloproliferative disorders [abstract]. Blood 1996;88(Suppl 1):479a.
23. Jantunen R, Juvonen E, Ikkala E, Okasanen K, Anttila P, Ruutu T. Development of erythrocytosis in the course of essential thrombocythemia. Ann Hematol 1999;78:219-222.
24. Pierre R, Imbert M, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Polycythaemia vera. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of tumors: pathology and genetics of tumours of the haematopoetic and lymphoid tissues. Lyon: IARC Press; 2001. p 32-34.
25. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
26. Yarbro JW. Mechanism of action of hydroxyurea. Sem Oncol 1992;19:1-10.
27. Murphy S. Therapeutic dilemmas: balancing the risk of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders. Thromb Haemost 1997;78:622-626.
28. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003;74:26-31.
29. Liu T-C. Multiple factors in the transformation of essential thrombocythemia to acute leukemia or myelodysplastic syndrome. Blood 1999;92:1465-1466.
30. Mesa R, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted county study, 1976-1995. Am J Hematol 1999;61:10-15.
31. Balaños-Meade J, Lopez-Arvizu C, Cobos E. Acute myeloid leukaemia arising from a patient with untreated essential thrombocythaemia. Eur J Haematol 2002;68:397-399.